73 related articles for article (PubMed ID: 36568792)
21. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions.
Yue P; Zhang M; Feng Y; Gao Y; Sun C; Chen P
Front Oncol; 2024; 14():1368804. PubMed ID: 38585010
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
24. Cemiplimab combined with chemotherapy
Zhu G; Cai H; Zheng Z
Ther Adv Med Oncol; 2023; 15():17588359231213619. PubMed ID: 38028144
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S; Kato K
Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
[TBL] [Abstract][Full Text] [Related]
26. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
Zheng Z; Lin J; Zhu H; Cai H
Front Public Health; 2022; 10():893387. PubMed ID: 35774581
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer.
Ye ZM; Xu Z; Wang HL; Wang YY; Chen ZC; Zhou Q; Li XP; Zhang YY
Cancer Med; 2023 Mar; 12(5):6182-6189. PubMed ID: 36271484
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Zhou Y; Peng L
Adv Ther; 2022 Jun; 39(6):2614-2629. PubMed ID: 35394255
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis.
Shen X; Huang S; Xiao H; Zeng S; Liu J; Ran Z; Xiong B
Eur J Hosp Pharm; 2023 Jan; 30(1):3-8. PubMed ID: 34497128
[TBL] [Abstract][Full Text] [Related]
34. Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies.
Hradska K; Hajek R; Jelinek T
Front Pharmacol; 2021; 12():733890. PubMed ID: 34483944
[TBL] [Abstract][Full Text] [Related]
35. Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US.
Allaire JC; Balk M; Azmi S; Handl HL; Yang K; Barnes G
Curr Med Res Opin; 2021 Aug; 37(8):1403-1407. PubMed ID: 33989092
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]